Compernolle G - Search Results

1

Real-world Endoscopic and Histological Outcomes Are Correlated with Ustekinumab Exposure in Patients with Ulcerative Colitis.

Alsoud D, De Hertogh G, Compernolle G, Tops S, Sabino J, Ferrante M, Thomas D, Vermeire S, Verstockt B. Alsoud D, et al. Among authors: compernolle g. J Crohns Colitis. 2022 Nov 1;16(10):1562-1570. doi: 10.1093/ecco-jcc/jjac067. J Crohns Colitis. 2022. PMID: 35533353

2

Ustekinumab Exposure-outcome Analysis in Crohn's Disease Only in Part Explains Limited Endoscopic Remission Rates.

Verstockt B, Dreesen E, Noman M, Outtier A, Van den Berghe N, Aerden I, Compernolle G, Van Assche G, Gils A, Vermeire S, Ferrante M. Verstockt B, et al. Among authors: compernolle g. J Crohns Colitis. 2019 Jul 25;13(7):864-872. doi: 10.1093/ecco-jcc/jjz008. J Crohns Colitis. 2019. PMID: 30715258

3

Evidence to Support Monitoring of Vedolizumab Trough Concentrations in Patients With Inflammatory Bowel Diseases.

Dreesen E, Verstockt B, Bian S, de Bruyn M, Compernolle G, Tops S, Noman M, Van Assche G, Ferrante M, Gils A, Vermeire S. Dreesen E, et al. Among authors: compernolle g. Clin Gastroenterol Hepatol. 2018 Dec;16(12):1937-1946.e8. doi: 10.1016/j.cgh.2018.04.040. Epub 2018 Apr 25. Clin Gastroenterol Hepatol. 2018. PMID: 29704680

4

Subcutaneous Absorption Contributes to Observed Interindividual Variability in Adalimumab Serum Concentrations in Crohn's Disease: A Prospective Multicentre Study.

Vande Casteele N, Baert F, Bian S, Dreesen E, Compernolle G, Van Assche G, Ferrante M, Vermeire S, Gils A. Vande Casteele N, et al. Among authors: compernolle g. J Crohns Colitis. 2019 Sep 27;13(10):1248-1256. doi: 10.1093/ecco-jcc/jjz050. J Crohns Colitis. 2019. PMID: 30820530

5

Anti-infliximab antibody concentrations can guide treatment intensification in patients with Crohn's disease who lose clinical response.

Dreesen E, Van Stappen T, Ballet V, Peeters M, Compernolle G, Tops S, Van Steen K, Van Assche G, Ferrante M, Vermeire S, Gils A. Dreesen E, et al. Among authors: compernolle g. Aliment Pharmacol Ther. 2018 Feb;47(3):346-355. doi: 10.1111/apt.14452. Epub 2017 Dec 11. Aliment Pharmacol Ther. 2018. PMID: 29226370

6

Antibodies Toward Vedolizumab Appear from the First Infusion Onward and Disappear Over Time.

Bian S, Dreesen E, Tang HT, Compernolle G, Peeters M, Van Assche G, Ferrante M, Vermeire S, Gils A. Bian S, et al. Among authors: compernolle g. Inflamm Bowel Dis. 2017 Dec;23(12):2202-2208. doi: 10.1097/MIB.0000000000001255. Inflamm Bowel Dis. 2017. PMID: 29140943

7

Evaluating Efficacy, Safety, and Pharmacokinetics After Switching From Infliximab Originator to Biosimilar CT-P13: Experience From a Large Tertiary Referral Center.

Bronswijk M, Moens A, Lenfant M, Tops S, Compernolle G, Van Assche G, Vermeire S, Gils A, Ferrante M. Bronswijk M, et al. Among authors: compernolle g. Inflamm Bowel Dis. 2020 Mar 4;26(4):628-634. doi: 10.1093/ibd/izz167. Inflamm Bowel Dis. 2020. PMID: 31400283

8

Endoscopic remission can be predicted by golimumab concentrations in patients with ulcerative colitis treated with the changed label.

Stefanovic S, Detrez I, Compernolle G, Brouwers E, Sever N, Stabuc B, Smrekar N, Kurent T, Novak G, Kozelj M, Ferrante M, Gils A, Drobne D. Stefanovic S, et al. Among authors: compernolle g. Eur J Gastroenterol Hepatol. 2021 Jan;33(1):54-61. doi: 10.1097/MEG.0000000000001843. Eur J Gastroenterol Hepatol. 2021. PMID: 32804854

9

Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease.

Vande Casteele N, Ferrante M, Van Assche G, Ballet V, Compernolle G, Van Steen K, Simoens S, Rutgeerts P, Gils A, Vermeire S. Vande Casteele N, et al. Among authors: compernolle g. Gastroenterology. 2015 Jun;148(7):1320-9.e3. doi: 10.1053/j.gastro.2015.02.031. Epub 2015 Feb 24. Gastroenterology. 2015. PMID: 25724455 Clinical Trial.

10

Generation and characterization of a unique panel of anti-adalimumab specific antibodies and their application in therapeutic drug monitoring assays.

Bian S, Stappen TV, Baert F, Compernolle G, Brouwers E, Tops S, Vries Ad, Rispens T, Lammertyn J, Vermeire S, Gils A. Bian S, et al. Among authors: compernolle g. J Pharm Biomed Anal. 2016 Jun 5;125:62-7. doi: 10.1016/j.jpba.2016.03.029. Epub 2016 Mar 15. J Pharm Biomed Anal. 2016. PMID: 27003121

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

35 results

Search Page